-
AstraZeneca elontersen approved in the United States
On December 21st local time, AstraZeneca announced that its and Ionis company's eplontersen have been approved in the United States. Eplontersen is an antisense oligonucleotide (ASO) therapy for the ... -
AstraZeneca acquires pharmaceutical company Amolyt Pharm for up to $1.05 billion
AstraZeneca announced on March 14th that it has signed a final agreement to acquire Amolyt Pharma, which has developed innovative therapeutic peptides for rare endocrine and metabolic diseases. Astra ... -
AstraZeneca acquires Amolyt Pharm for up to $1.05 billion
Beijing Business Daily (Reporter Yao Qian) On March 14th, AstraZeneca announced that it had signed a final agreement to acquire Amolyt Pharma, which has developed innovative therapeutic peptides for ... -
Multinational pharmaceutical company ramps up nuclear medicine track, AstraZeneca acquires Fusion for $2.4 billion
On March 19th local time, AstraZeneca announced that it will spend $2.4 billion to acquire the biopharmaceutical company Fusion Pharmaceuticals, and a final agreement has been reached. The acquisitio ... -
AstraZeneca breast cancer treatment trial failed to meet expectations
[AstraZeneca's breast cancer treatment trial did not meet expectations] AstraZeneca announced that the experimental anti-cancer drug Dato DXD, which was jointly developed with Daiichi Sankyo, failed ...